[1]
|
Young, L.S., Yap, L.F. and Murray, P.G. (2016) Epstein-Barr Virus: More than 50 Years Old and Still Providing Surprises. Nature Reviews Cancer, 16, 789. https://doi.org/10.1038/nrc.2016.92
|
[2]
|
Cohen, M., Narbaitz, M., Metrebian, F., et al. (2014) Epstein-Barr Virus-Positive Diffuse Large B-Cell Lymphoma Association Is Not Only Restricted to Elderly Patients. International Journal of Cancer, 135, 2816-2824.
https://doi.org/10.1002/ijc.28942
|
[3]
|
Molyneux, E.M., Rochford, R., Griffin, B., et al. (2012) Burkitt’s Lymphoma. The Lancet, 379, 1234-1244.
https://doi.org/10.1016/S0140-6736(11)61177-X
|
[4]
|
Thorley-Lawson, D.A. (2001) Epstein-Barr Virus: Exploiting the Immune System. Nature Reviews Immunology, 1, 75-82. https://doi.org/10.1038/35095584
|
[5]
|
Jiang, X.N., Yu, B.H., Yan, W.H., Lee, J., Zhou, X.Y. and Li, X.Q. (2019) Epstein-Barr Virus-Positive Diffuse Large B-Cell Lymphoma Features Disrupted Antigen Capture/Presentation and Hijacked T-Cell Suppression. Oncoimmunology, 9, Article ID: 1683346. https://doi.org/10.1080/2162402X.2019.1683346
|
[6]
|
Long, H.M. (2018) Targeting EBV-Positive B- and T/NK-Cell Lymphomas. Blood, 132, 2315-2316.
https://doi.org/10.1182/blood-2018-10-878587
|
[7]
|
Hislop, A.D., Kuo, M., Drake-Lee, A.B., et al. (2005) Tonsillar Homing of Epstein-Barr Virus-Specific CD8+ T Cells and the Virus-Host Balance. Journal of Clinical Investigation, 115, 2546-2555. https://doi.org/10.1172/JCI24810
|
[8]
|
Woon, H.G., Braun, A., Li, J., et al. (2016) Compartmentalization of Total and Virus-Specific Tissue-Resident Memory CD8+ T Cells in Human Lymphoid Organs. PLOS Pathogens, 12, e1005799.
https://doi.org/10.1371/journal.ppat.1005799
|
[9]
|
Morscio, J., Finalet Ferreiro, J., Vander Borght, S., et al. (2017) Identification of Distinct Subgroups of EBV-Positive Post-Transplant Diffuse Large B-Cell Lymphoma. Modern Pathology, 30, 370-381.
https://doi.org/10.1038/modpathol.2016.199
|
[10]
|
Perret, J.L., Moussavou-Kombila, J.B., Delaporte, E., et al. (2003) Prevalence of Hepatitis B and C Virus, HTLV-1 and HIV in Type B Lymphoproliferative Syndromes in Gabon. Bulletin de la Société de Pathologie Exotique, 96, 275-278.
|
[11]
|
Ogembo, J.G., Muraswki, M.R., McGinnes, L.W., et al. (2015) A Chimeric EBV gp350/220-Based VLP Replicates the Virion B-Cell Attachment Mechanism and Elicits Long-Lasting Neutralizing Antibodies in Mice. Journal of Translational Medicine, 13, 50. https://doi.org/10.1186/s12967-015-0415-2
|
[12]
|
Queiroga, E.M., Gualco, G., Weiss, L.M., et al. (2008) Burkitt Lymphoma in Brazil Is Characterized by Geographically Distinct Clinicopathologic Features. American Journal of Clinical Pathology, 130, 946-956.
https://doi.org/10.1309/AJCP64YOHAWLUMPK
|
[13]
|
Guech-Ongey, M., Simard, E.P., Anderson, W.F., et al. (2010) AIDS-Related Burkitt Lymphoma in the United States: What Do Age and CD4 Lymphocyte Patterns Tell Us about Etiology and/or Biology? Blood, 116, 5600-5604.
https://doi.org/10.1182/blood-2010-03-275917
|
[14]
|
中华医学会血液学分会. 中国弥漫大B细胞淋巴瘤诊断与治疗指南(2013年版) [J]. 中华血液学杂志, 2013, 34(9): 816-819.
|
[15]
|
陈少红, 叶子茵, 杨静, 等. 老年性EBV阳性弥漫性大B细胞淋巴瘤临床病理特征[J]. 诊断病理学杂志, 2015(11): 661-664+668.
|
[16]
|
Alizadeh, A.A., Eisen, M.B., Davis, R.E., et al. (2000) Distinct Types of Diffuse Large B-Cell Lymphoma Identified by Gene Expression Profiling. Nature, 403, 503-511. https://doi.org/10.1038/35000501
|
[17]
|
Pasqualucci, L. and Dalla-Favera, R. (2015) The Genetic Landscape of Diffuse Large B-Cell Lymphoma. Seminars in Hematology, 52, 67-76. https://doi.org/10.1053/j.seminhematol.2015.01.005
|
[18]
|
Jaffe, E., Swerdlow, S.H.C.E., Campo, E., et al. (2008) WHO Classification of Tumours of the Haematopoietic and Lymphoid Tissues. IARC, Lyon.
|
[19]
|
Nicolae, A., Pittaluga, S., Abdullah, S., et al. (2015) EBV-Positive Large B-Cell Lymphomas in Young Patients: A Nodal Lymphoma with Evidence for a Tolerogenic Immune Environment. Blood, 126, 863-872.
https://doi.org/10.1182/blood-2015-02-630632
|
[20]
|
Said, J. (2015) The Expanding Spectrum of EBV+ Lymphomas. Blood, 126, 827-828.
https://doi.org/10.1182/blood-2015-06-648097
|
[21]
|
Cohen, M., Vistarop, A.G., Huaman, F., et al. (2017) Cytotoxic Response against Epstein Barr Virus Coexists with Diffuse Large B-Cell Lymphoma Tolerogenic Microenvironment: Clinical Features and Survival Impact. Scientific Reports, 7, Article No. 10813. https://doi.org/10.1038/s41598-017-11052-z
|
[22]
|
Swerdlow, S.H., Campo, E., Pileri, S.A., et al. (2016) The 2016 Revision of the World Health Organization Classification of Lymphoid Neoplasms. Blood, 127, 2375-2390. https://doi.org/10.1182/blood-2016-01-643569
|
[23]
|
Adam, P., Bonzheim, I., Fend, F., et al. (2011) Epstein-Barr Virus-Positive Diffuse Large B-Cell Lymphomas of the Elderly. Advances in Anatomic Pathology, 18, 349-355. https://doi.org/10.1097/PAP.0b013e318229bf08
|
[24]
|
Hoeller, S., Tzankov, A., Pileri, S.A., et al. (2010) Epstein-Barr Virus-Positive Diffuse Large B-Cell Lymphoma in Elderly Patients Is Rare in Western Populations. Human Pathology, 41, 352-357.
https://doi.org/10.1016/j.humpath.2009.07.024
|
[25]
|
Oyama, T., Yamamoto, K., Asano, N., et al. (2007) Age-Related EBV-Associated B-Cell Lymphoproliferative Disorders Constitute a Distinct Clinicopathologic Group: A Study of 96 Patients. Clinical Cancer Research, 13, 5124-5132.
https://doi.org/10.1158/1078-0432.CCR-06-2823
|
[26]
|
Cardenas, D., Velez, G., Orfao, A., et al. (2015) Epstein-Barr Virus-Specific CD8(+) T Lymphocytes from Diffuse Large B Cell Lymphoma Patients Are Functionally Impaired. Clinical and Experimental Immunology, 182, 173-183.
https://doi.org/10.1111/cei.12682
|
[27]
|
Ok, C.Y., Papathomas, T.G., Medeiros, L.J., et al. (2013) EBV-Positive Diffuse Large B-Cell Lymphoma of the Elderly. Blood, 122, 328-340. https://doi.org/10.1182/blood-2013-03-489708
|
[28]
|
White, R.E., Ramer, P.C., Naresh, K.N., et al. (2012) EBNA3B-Deficient EBV Promotes B Cell Lymphomagenesis in Humanized Mice and Is Found in Human Tumors. Journal of Clinical Investigation, 122, 1487-1502.
https://doi.org/10.1172/JCI58092
|
[29]
|
Sebastian, E., Alcoceba, M., Martin-Garcia, D., et al. (2016) High-Resolution Copy Number Analysis of Paired Normal-Tumor Samples from Diffuse Large B Cell Lymphoma. Annals of Hematology, 95, 253-262.
https://doi.org/10.1007/s00277-015-2552-3
|
[30]
|
Shaffer, A.L., Young, R.M. and Staudt, L.M. (2012) Pathogenesis of Human B Cell Lymphomas. Annual Review of Immunology, 30, 565-610. https://doi.org/10.1146/annurev-immunol-020711-075027
|
[31]
|
Mandelbaum, J., Bhagat, G., Tang, H., et al. (2010) BLIMP1 Is a Tumor Suppressor Gene Frequently Disrupted in Activated B Cell-Like Diffuse Large B Cell Lymphoma. Cancer Cell, 18, 568-579.
https://doi.org/10.1016/j.ccr.2010.10.030
|
[32]
|
Pasqualucci, L., Compagno, M., Houldsworth, J., et al. (2006) Inactivation of the PRDM1/BLIMP1 Gene in Diffuse Large B Cell Lymphoma. Journal of Experimental Medicine, 203, 311-317. https://doi.org/10.1084/jem.20052204
|
[33]
|
Tam, W., Gomez, M., Chadburn, A., et al. (2006) Mutational Analysis of PRDM1 Indicates a Tumor-Suppressor Role in Diffuse Large B-Cell Lymphomas. Blood, 107, 4090-4100. https://doi.org/10.1182/blood-2005-09-3778
|
[34]
|
Lam, L., Davis, R., Pierce, J., et al. (2005) Small Molecule Inhibitors of IkappaB Kinase Are Selectively Toxic for Subgroups of Diffuse Large B-Cell Lymphoma Defined by Gene Expression Profiling. Clinical Cancer Research, 11, 28-40.
|
[35]
|
Kato, H., Karube, K., Yamamoto, K., et al. (2014) Gene Expression Profiling of Epstein-Barr Virus-Positive Diffuse Large B-Cell Lymphoma of the Elderly Reveals Alterations of Characteristic Oncogenetic Pathways. Cancer Science, 105, 537-544. https://doi.org/10.1111/cas.12389
|
[36]
|
Loong, F., Chan, A.C., Ho, B.C., et al. (2010) Diffuse Large B-Cell Lymphoma Associated with Chronic Inflammation as an Incidental Finding and New Clinical Scenarios. Modern Pathology, 23, 493-501.
https://doi.org/10.1038/modpathol.2009.168
|
[37]
|
Sanchez-Gonzalez, B., Garcia, M., Montserrat, F., et al. (2013) Diffuse Large B-Cell Lymphoma Associated with Chronic Inflammation in Metallic Implant. Journal of Clinical Oncology, 31, e148-e151.
https://doi.org/10.1200/JCO.2012.42.8250
|
[38]
|
Kanno, H., Naka, N., Yasunaga, Y., et al. (1997) Production of the Immunosuppressive Cytokine Interleukin-10 by Epstein-Barr-Virus-Expressing Pyothorax-Associated Lymphoma: Possible Role in the Development of Overt Lymphoma in Immunocompetent Hosts. The American Journal of Pathology, 150, 349-357.
|
[39]
|
Kanno, H., Naka, N., Yasunaga, Y., et al. (1997) Role of an Immunosuppressive Cytokine, Interleukin-10, in the Development of Pyothorax-Associated Lymphoma. Leukemia, 11, 525-526.
|
[40]
|
Kanno, H., Yasunaga, Y., Iuchi, K., et al. (1996) Interleukin-6-Mediated Growth Enhancement of Cell Lines Derived from Pyothorax-Associated Lymphoma. Laboratory Investigation, 75, 167-173.
|
[41]
|
Kanno, H., Ohsawa, M., Hashimoto, M., et al. (1999) HLA-A Alleles of Patients with Pyothorax-Associated Lymphoma: Anti-Epstein-Barr Virus (EBV) Host Immune Responses during the Development of EBV Latent Antigen-Positive Lymphomas. International Journal of Cancer, 82, 630-634.
https://doi.org/10.1002/(SICI)1097-0215(19990827)82:5<630::AID-IJC2>3.0.CO;2-D
|
[42]
|
Kanno, H., Nakatsuka, S., Iuchi, K., et al. (2000) Sequences of Cytotoxic T-Lymphocyte Epitopes in the Epstein-Barr Virus (EBV) Nuclear Antigen-3B Gene in a Japanese Population with or without EBV-Positive Lymphoid Malignancies. International Journal of Cancer, 88, 626-632.
https://doi.org/10.1002/1097-0215(20001115)88:4<626::AID-IJC17>3.0.CO;2-Q
|
[43]
|
Nishiu, M., Tomita, Y., Nakatsuka, S., et al. (2004) Distinct Pattern of Gene Expression in Pyothorax-Associated Lymphoma (PAL), a Lymphoma Developing in Long-Standing Inflammation. Cancer Science, 95, 828-834.
https://doi.org/10.1111/j.1349-7006.2004.tb02189.x
|
[44]
|
Cesarman, E. (2013) Pathology of Lymphoma in HIV. Current Opinion in Oncology, 25, 487-494.
https://doi.org/10.1097/01.cco.0000432525.70099.a4
|
[45]
|
Arvey, A., Ojesina, A.I., Pedamallu, C.S., et al. (2015) The Tumor Virus Landscape of AIDS-Related Lymphomas. Blood, 125, e14-e22. https://doi.org/10.1182/blood-2014-11-599951
|
[46]
|
Epstein, M.A., Achong, B.G. and Barr, Y.M. (1964) Virus Particles in Cultured Lymphoblasts from Burkitt’s Lymphoma. The Lancet, 1, 702-703. https://doi.org/10.1016/S0140-6736(64)91524-7
|
[47]
|
Burkitt, D.P. (1969) Etiology of Burkitt’s Lymphoma—An Alternative Hypothesis to a Vectored Virus. Journal of the National Cancer Institute, 42, 19-28.
|
[48]
|
Geser, A., de The, G., Lenoir, G., et al. (1982) Final Case Reporting from the Ugandan Prospective Study of the Relationship between EBV and Burkitt’s Lymphoma. International Journal of Cancer, 29, 397-400.
https://doi.org/10.1002/ijc.2910290406
|
[49]
|
Niedobitek, G., Agathanggelou, A., Rowe, M., et al. (1995) Heterogeneous Expression of Epstein-Barr Virus Latent Proteins in Endemic Burkitt’s Lymphoma. Blood, 86, 659-665.
https://doi.org/10.1182/blood.V86.2.659.bloodjournal862659
|
[50]
|
Kelly, G., Bell, A. and Rickinson, A. (2002) Epstein-Barr Virus-Associated Burkitt Lymphomagenesis Selects for Downregulation of the Nuclear Antigen EBNA2. Nature Medicine, 8, 1098-1104. https://doi.org/10.1038/nm758
|
[51]
|
Kelly, G.L., Milner, A.E., Tierney, R.J., et al. (2005) Epstein-Barr Virus Nuclear Antigen 2 (EBNA2) Gene Deletion Is Consistently Linked with EBNA3A, -3B, and -3C Expression in Burkitt’s Lymphoma Cells and with Increased Resistance to Apoptosis. Journal of Virology, 79, 10709-10717. https://doi.org/10.1128/JVI.79.16.10709-10717.2005
|
[52]
|
Rowe, M., Kelly, G.L., Bell, A.I., et al. (2009) Burkitt’s Lymphoma: The Rosetta Stone Deciphering Epstein-Barr Virus Biology. Seminars in Cancer Biology, 19, 377-388. https://doi.org/10.1016/j.semcancer.2009.07.004
|
[53]
|
Paschos, K., Smith, P., Anderton, E., et al. (2009) Epstein-Barr Virus Latency in B Cells Leads to Epigenetic Repression and CpG Methylation of the Tumour Suppressor Gene Bim. PLOS Pathogens, 5, e1000492.
https://doi.org/10.1371/journal.ppat.1000492
|
[54]
|
Kamranvar, S.A., Gruhne, B., Szeles, A., et al. (2007) Epstein-Barr Virus Promotes Genomic Instability in Burkitt’s Lymphoma. Oncogene, 26, 5115-5123. https://doi.org/10.1038/sj.onc.1210324
|
[55]
|
Holowaty, M.N., Zeghouf, M., Wu, H., et al. (2003) Protein Profiling with Epstein-Barr Nuclear Antigen-1 Reveals an Interaction with the Herpesvirus-Associated Ubiquitin-Specific Protease HAUSP/USP7. Journal of Biological Chemistry, 278, 29987-29994. https://doi.org/10.1074/jbc.M303977200
|
[56]
|
Li, M., Chen, D., Shiloh, A., et al. (2002) Deubiquitination of p53 by HAUSP Is an Important Pathway for p53 Stabilization. Nature, 416, 648-653. https://doi.org/10.1038/nature737
|
[57]
|
Li, M., Brooks, C.L., Kon, N., et al. (2004) A Dynamic Role of HAUSP in the p53-Mdm2 Pathway. Molecular Cell, 13, 879-886. https://doi.org/10.1016/S1097-2765(04)00157-1
|
[58]
|
Holowaty, M.N., Sheng, Y., Nguyen, T., et al. (2003) Protein Interaction Domains of the Ubiquitin-Specific Protease, USP7/HAUSP. Journal of Biological Chemistry, 278, 47753-47761. https://doi.org/10.1074/jbc.M307200200
|
[59]
|
Saridakis, V., Sheng, Y., Sarkari, F., et al. (2005) Structure of the p53 Binding Domain of HAUSP/USP7 Bound to Epstein-Barr Nuclear Antigen 1 Implications for EBV-Mediated Immortalization. Molecular Cell, 18, 25-36.
https://doi.org/10.1016/j.molcel.2005.02.029
|
[60]
|
Sheng, Y., Saridakis, V., Sarkari, F., et al. (2006) Molecular Recognition of p53 and MDM2 by USP7/HAUSP. Nature Structural & Molecular Biology, 13, 285-291. https://doi.org/10.1038/nsmb1067
|
[61]
|
Lu, J., Murakami, M., Verma, S.C., et al. (2011) Epstein-Barr Virus Nuclear Antigen 1 (EBNA1) Confers Resistance to Apoptosis in EBV-Positive B-Lymphoma Cells through Up-Regulation of Survivin. Virology, 410, 64-75.
https://doi.org/10.1016/j.virol.2010.10.029
|
[62]
|
Hochberg, D., Middeldorp, J.M., Catalina, M., et al. (2004) Demonstration of the Burkitt’s Lymphoma Epstein-Barr Virus Phenotype in Dividing Latently Infected Memory Cells in Vivo. Proceedings of the National Academy of Sciences of the United States of America, 101, 239-244. https://doi.org/10.1073/pnas.2237267100
|
[63]
|
Bellan, C., Lazzi, S., Hummel, M., et al. (2005) Immunoglobulin Gene Analysis Reveals 2 Distinct Cells of Origin for EBV-Positive and EBV-Negative Burkitt Lymphomas. Blood, 106, 1031-1036.
https://doi.org/10.1182/blood-2005-01-0168
|
[64]
|
Pileri, S.A., Ascani, S., Leoncini, L., et al. (2002) Hodgkin’s Lymphoma: The Pathologist’s Viewpoint. Journal of Clinical Pathology, 55, 162-176. https://doi.org/10.1136/jcp.55.3.162
|
[65]
|
Mathas, S., Hartmann, S. and Kuppers, R. (2016) Hodgkin Lymphoma: Pathology and Biology. Seminars in Hematology, 53, 139-147. https://doi.org/10.1053/j.seminhematol.2016.05.007
|
[66]
|
Aldinucci, D., Celegato, M. and Casagrande, N. (2016) Microenvironmental Interactions in Classical Hodgkin Lymphoma and Their Role in Promoting Tumor Growth, Immune Escape and Drug Resistance. Cancer Letters, 380, 243-252.
https://doi.org/10.1016/j.canlet.2015.10.007
|
[67]
|
Glaser, S.L., Lin, R.J., Stewart, S.L., et al. (1997) Epstein-Barr Virus-Associated Hodgkin’s Disease: Epidemiologic Characteristics in International Data. International Journal of Cancer, 70, 375-382.
https://doi.org/10.1002/(SICI)1097-0215(19970207)70:4<375::AID-IJC1>3.0.CO;2-T
|
[68]
|
Carroll, V. and Garzino-Demo, A. (2015) HIV-Associated Lymphoma in the Era of Combination Antiretroviral Therapy: Shifting the Immunological Landscape. Pathogens and Disease, 73, ftv044. https://doi.org/10.1093/femspd/ftv044
|
[69]
|
Vockerodt, M., Morgan, S.L., Kuo, M., et al. (2008) The Epstein-Barr Virus Oncoprotein, Latent Membrane Protein-1, Reprograms Germinal Centre B Cells towards a Hodgkin’s Reed-Sternberg-Like Phenotype. The Journal of Pathology, 216, 83-92. https://doi.org/10.1002/path.2384
|
[70]
|
Vrzalikova, K., Vockerodt, M., Leonard, S., et al. (2011) Down-Regulation of BLIMP1alpha by the EBV Oncogene, LMP-1, Disrupts the Plasma Cell Differentiation Program and Prevents Viral Replication in B Cells: Implications for the Pathogenesis of EBV-Associated B-Cell Lymphomas. Blood, 117, 5907-5917.
https://doi.org/10.1182/blood-2010-09-307710
|
[71]
|
Vockerodt, M., Wei, W., Nagy, E., et al. (2013) Suppression of the LMP2A Target Gene, EGR-1, Protects Hodgkin’s Lymphoma Cells from Entry to the EBV Lytic Cycle. The Journal of Pathology, 230, 399-409.
https://doi.org/10.1002/path.4198
|
[72]
|
Brauninger, A., Schmitz, R., Bechtel, D., et al. (2006) Molecular Biology of Hodgkin’s and Reed/Sternberg Cells in Hodgkin’s Lymphoma. International Journal of Cancer, 118, 1853-1861. https://doi.org/10.1002/ijc.21716
|
[73]
|
Schmitz, R., Hansmann, M.L., Bohle, V., et al. (2009) TNFAIP3 (A20) Is a Tumor Suppressor Gene in Hodgkin Lymphoma and Primary Mediastinal B Cell Lymphoma. Journal of Experimental Medicine, 206, 981-989.
https://doi.org/10.1084/jem.20090528
|
[74]
|
Renne, C., Hinsch, N., Willenbrock, K., et al. (2007) The Aberrant Coexpression of Several Receptor Tyrosine Kinases Is Largely Restricted to EBV-Negative Cases of Classical Hodgkin’s Lymphoma. International Journal of Cancer, 120, 2504-2509. https://doi.org/10.1002/ijc.22511
|
[75]
|
Leonard, S., Wei, W., Anderton, J., et al. (2011) Epigenetic and Transcriptional Changes which Follow Epstein-Barr Virus Infection of Germinal Center B Cells and Their Relevance to the Pathogenesis of Hodgkin’s Lymphoma. Journal of Virology, 85, 9568-9577. https://doi.org/10.1128/JVI.00468-11
|